Fantofarone (SR33557): effects on myocardial oxygen consumption and coronary blood flow.
We have investigated the effects of a novel calcium antagonist, fantofarone (SR 33557) on myocardial oxygen consumption (MO2C) and coronary blood flow in anaesthetized dogs during periods of normal and elevated heart rate. 25 micrograms/kg i.v. fantofarone induced a transient increase in coronary blood flow (+25% after 2 min; p < 0.05) and a more sustained decrease in MO2C (-50% after 5 min; p < 0.05). During the periods of pacing, these alterations on cardiac function were not evident. Administration of 50 micrograms/kg i.v. resulted in similar modifications of cardiac function; however, these changes were apparent for a longer duration. Coronary blood flow was still significantly elevated by 29% 2 min after drug administration (p < 0.01) and MO2C was reduced by 67% after 5 min (p < 0.01) and by 56% after 30 min (p < 0.05). Most importantly, a significant decrease in MO2C was observed during the pacing periods (32% after 10 min; p < 0.01). Thus fantofarone can significantly modify cardiac function and in particular, decrease MO2C consumption during periods of elevated heart rate.
Hodeige
D
D
S.A. Sanofi-Pharma N.V., Brussels, Belgium.
Chatelain
P
P
Manning
A
A
D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects*; D004285:Dogs; D006321:Heart / Q000502:physiology; D006339:Heart Rate; D006439:Hemodynamics / Q000187:drug effects; D007212:Indolizines / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects*; D010627:Phenethylamines / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D007212:Indolizines; D010627:Phenethylamines; C059901:fantofarone